RT Journal Article
SR Electronic
T1 Infectiousness in omicron variant strain and bA.2 variant in Japan
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.20.21259209
DO 10.1101/2021.06.20.21259209
A1 Kurita, Junko
A1 Sugawara, Tamie
A1 Ohkusa, Yasushi
YR 2022
UL http://medrxiv.org/content/early/2022/05/27/2021.06.20.21259209.abstract
AB Background Omicron variant strain dominated since the beginning of 2022. Its infectivity was supposes to be higher than Delta variant strain or strains in past.Object We estimated prevalence of omicron variant strain, particularly bA.2 variant and COVID-19 vaccine effectiveness of the third dose in Japan as well as controlling for waning of second dose of vaccine, other mutated strains, the Olympic Games, and countermeasures.Method The effective reproduction number R(t) was regressed on shares of omicron variant strain and bA.2 and vaccine coverage of the third dose, as well as along with data of temperature, humidity, mobility, share of the other mutated strains, and an Olympic Games and countermeasures. The study period was February, 2020 through February 21, 2022, as of March 15, 2022.Results Estimation results indicated that waning of the second dose vaccine e with 150 days prior was the most appropriate specification. Moreover, bA.2 of omicron variant strain has higher infectively than other variant strain or traditional strain.Discussion Because of data limitation since emerging bA.2, the estimated its infectively will change over time.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All information used for this study has been published. There is therefore no ethical issue related to this study. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesJapan Ministry of Health, Labour and Welfare. Press Releases.(in Japanese) https://www.mhlw.go.jp/stf/newpage_10723.html